The blood-brain barrier (BBB) is a dynamic structure that functions as a gatekeeper,
reflecting the unique requirements of the brain. In this review, following a brief historical …

Radiotracers for imaging protein targets in the living human brain with positron emission
tomography (PET) are increasingly useful in clinical research and in drug development …

Resistance to drug treatment is an important hurdle in the therapy of many brain disorders,
including brain cancer, epilepsy, schizophrenia, depression and infection of the brain with …

Despite scientific advances in understanding the causes and treatment of human
malignancy, a persistent challenge facing basic and clinical investigators is how to …

The blood–brain barrier (BBB) serves as a protective mechanism for the brain by preventing
entry of potentially harmful substances from free access to the central nervous system …

Human in vivo molecular imaging with positron emission tomography (PET) enables a new
kind of 'precision pharmacology', able to address questions central to drug development …

Alzheimer's disease is a neurodegenerative disorder in which the pathological accumulation
of amyloid-β and tau begins years before symptom onset. Emerging evidence suggests that …

Drug‐resistant epilepsy with uncontrolled severe seizures despite state‐of‐the‐art medical
treatment continues to be a major clinical problem for up to one in three patients with …

Noninvasive molecular imaging approaches include nuclear, optical, magnetic resonance
imaging, computed tomography, ultrasound, and photoacoustic imaging, which require …

The development of novel neuropharmaceuticals requires the evaluation of blood–brain
barrier (BBB) permeability and toxicity. Recent studies have highlighted differences in the …